ArticleNeuroimmunomodulation2026
The Participation of Prolactin in the Immunopathology of Experimental Pulmonary Tuberculosis.
Article in Neuroimmunomodulation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProlactin and its receptor are widely recognized for their roles in lactogenesis and galactopoiesis. However, they have also gained attention for their role in immune pathophysiology, acting as mediators of both innate and acquired immune responses and potentially playing a significant role in chronic infectious diseases such as tuberculosis.
methodsIn this study, we examined the kinetics of prolactin and its receptor during the progression of experimental pulmonary tuberculosis in BALB/c mice infected intratracheally with a high-dose Mycobacterium tuberculosis (M. tuberculosis) reference strain, H37Rv. Groups of infected mice were euthanized at various time points, and their lungs were collected to quantify gene expression of prolactin and its receptor by RT-PCR, as well as to assess cellular expression by immunohistochemistry. In vitro infection experiments with alveolar macrophages and type II pneumocyte cell lines were conducted to evaluate the effects of prolactin on bacteriolysis and the expression of various innate immune response factors. After 2 months of infection, BALB/c mice with progressive pulmonary tuberculosis were treated with ovine PRL, and the effects were assessed by measuring bacillary loads and the extent of tissue damage (pneumonia).
resultsIn vitro studies showed that prolactin increases bacterial phagocytosis in alveolar macrophages and significantly enhances the production of reactive oxygen and nitrogen species, which reduces bacillary loads. In type II pneumocytes, prolactin, under certain conditions, induces higher, though not statistically significant, expression of cathelicidin and surfactant proteins A and D. In vivo studies revealed that, during early infection (within the first week), there was high expression of prolactin and its receptor in the lungs. Immunostaining for prolactin and its receptor was observed at the early stage of infection, mainly in alveolar epithelial cells, macrophages, and lymphocytes. During the second week of infection, immunostaining showed the organization of macrophages and lymphocytes within granulomas and in the inflammatory infiltrate around blood vessels and airways, with macrophages showing the strongest staining. Over the course of progressive disease, after 1 month of infection, pulmonary prolactin production decreased, and some macrophages and lymphocytes showed minimal prolactin immunostaining, although high prolactin receptor expression persisted; 4 months later, prolactin immunostaining was observed in the bronchial epithelium. Administration of prolactin via intraperitoneal injection 2 months after infection resulted in a significant reduction in bacillary loads after 2 months of treatment, along with increased but not statistically significant expression of TNFα and IFNγ.
conclusionsProlactin and its receptors appear to contribute to immune activation during pulmonary tuberculosis, particularly in the early stages of infection. Prolactin administration during late active disease reactivates immune protection. Although we do not demonstrate the mechanisms underlying these observations, these results could serve as a basis for expanding future experimental research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.